Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.985 SEK | -1.97% |
|
-3.04% | +7.70% |
Jul. 02 | Q-linea Takes Part in First Belgian Public Tender for Rapid AST System | MT |
Jun. 28 | Q-linea AB Approves the Election of Jonas Jarvius as Members of the Board of Directors | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.70% | 44.41M | C | ||
-30.79% | 15.65B | A | ||
-57.58% | 2.09B | C+ | ||
+19.25% | 1.88B | - | ||
-18.17% | 1.36B | - | ||
+25.65% | 1.28B | B+ | ||
+2.06% | 798M | - | ||
-33.66% | 762M | - | ||
-36.55% | 724M | - | C- | |
-30.00% | 586M | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QLINEA Stock
- Ratings Q-linea AB